Loading
Almirall, S.A. Stock: price and insider trades · Spain
No insider purchase over the last 90 days. The latest was filed 22 Jun 2023.
Almirall, S.A.: what insiders have been doing
Headquartered in Barcelona, Spain, Almirall, S.A. belongs to the Health Care sector and traces its origins to 1943. Filings by its managers are published through CNMV. Nothing new has been filed by managers of Almirall, S.A. in twelve months, the latest record being from 22 June 2023.
Since 2021, the database holds 5 purchases and 2 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by CNMV. They describe what insiders did and are not a recommendation.
Insider Decl.
20
Thresholds
n/a
Buy Volume
€190,917
5 ops. · all time
Sell Volume
€7M
2 ops. · all time
Since the insiders bought
- +23.0%Entry €7.82 · Close at T+365 €9.63
- +20.6%Entry €7.98 · Close at T+365 €9.62
- +18.8%Entry €8.15 · Close at T+365 €9.69
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Almirall, S.A. Strong Buy (bullish), based on 12 analysts. Average price target: €14.51.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,556 of 24,148 companies
52.6
score / 100
Value46
Quality59
FCF yld1.5%
Earn yld1.9%
EV/EBITDA11.8x
ROE4.0%
Gross mgn79%
Net mgn4.2%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€11.10
Analyst consensus
12 analystsStrong buy
€12.50Target €14.51(+31%)€17.50
Income statement
Revenue€1.1B
Gross profit€871.6M79% margin
EBITDA€234.0M21% margin
Net income€46.2M5.1% margin
Valuation
PER (trailing)39.6x
PER (forward)20.2x
P/Book1.6x
Beta0.18
Balance sheet & cash
Market cap€2.4B
Total debt€342.9M
Free Cash Flow€37.2M
Debt / Equity24%
Profitability & ownership
ROE4.0%
ROA2.7%
% insiders64.1%
% institutions17.7%
Last declaration on 22 June 2023
Declarations20 total
3,000 shares@ €8.700.0011% mcap22.8% of flowShareXMADISIN ES0157097017CNMV:2023076666
Canonical exit: 3 Sept 2023 (T+90)
5,000 shares@ €7.990.0016% mcap34.9% of flowShareXMADISIN ES0157097017CNMV:2023076670
Canonical exit: 11 Sept 2023 (T+90)
6,000 shares@ €8.050.0020% mcap42.2% of flowShareXMADISIN ES0157097017CNMV:2023076672
Canonical exit: 13 Sept 2023 (T+90)
4,340 shares@ €8.080.0014% mcap100.0% of flowShareXMADISIN ES0157097017CNMV:2023076025
Canonical exit: 18 Sept 2023 (T+90)
5,000 shares@ €8.300.0017% mcap100.0% of flowShareXMADISIN ES0157097017CNMV:2023067299
Canonical exit: 24 Aug 2023 (T+90)
42 shares@ €0.190.0% of flowDerivativeXMADISIN ES0157097017CNMV:2021080117
16,772,234 shares@ €0.18100.0% of flowDerivativeXOFFISIN ES0157097017CNMV:2021080106
36,491,040 shares@ €0.18100.0% of flowDerivativeXOFFISIN ES0157097017CNMV:2021080116
243,076 shares0ShareXOFFISIN ES0157097017CNMV:2021080108
528,854 shares0ShareXOFFISIN ES0157097017CNMV:2021080118
20 of 20 declarations
About Almirall, S.A.
Almirall, S.A. is a Spanish pharmaceutical company focused on developing dermatological and respiratory treatments. It is listed on the Spanish stock market XMAD.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
